NewslettersHuman Immunology NewsImmune Regulation NewsIntestinal Cell News Surrozen Initiates Dosing in Phase I Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis By Danielle Corrigan - May 19, 2022 0 Surrozen, Inc. announced that the first subject has been dosed in its three-part Phase I clinical trial to evaluate SZN-1326 for the potential treatment of moderate to severe ulcerative colitis. [Surrozen, Inc.] Press Release